US FDA Approves Novartis’ New Kidney Disease Drug, Fabhalta 2 minutes read News US FDA Approves Novartis’ New Kidney Disease Drug, Fabhalta wbstadmin August 8, 2024 0 US FDA Approves Novartis’ Fabhalta for IgA Nephropathy, Showing 44% Reduction in Urine Protein Levels. Read More Read more about US FDA Approves Novartis’ New Kidney Disease Drug, Fabhalta
